mRNA technology Archives

biocatalysis pseudouridine mRNA vaccines

More News! 25 Apr 2023

More efficient and cost-effective mRNA vaccines developed

A new and patented method for the production of the important mRNA vaccine component pseudouridine is more efficient, sustainable and cost-effective than the previously used chemical synthesis. Researchers from the Institute of Biotechnology and Biochemical Engineering at TU Graz and the Austrian Centre of Industrial Biotechnology (acib) have developed a novel method for the production […]

April 25, 2023 - 3 minutesmins - By Jim Cornall

In Depth 14 Apr 2023

mRNA vaccines: a promising future

In 1978, nearly two decades after the discovery of messenger RNA (mRNA), the concept of a vaccine made from mRNA was materialized. Like its name suggests, mRNAs are messengers that aid in decoding genetic information from DNA to synthesize proteins, a key cellular function. Previous attempts at developing a vaccine using mRNA failed because mRNA […]

April 14, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 17 Mar 2023

Likang gets trial ok for China’s first personalized cancer vaccine

Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 injection. This is the first personalized neoantigen vaccine and mRNA editing product approved by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to enter the clinical stage. Likang submitted […]

March 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 8 Mar 2023

Could changing mRNA provide a new target for Alzheimer’s disease?

Reducing the methylation of a key messenger RNA can promote migration of macrophages into the brain and ameliorate symptoms of Alzheimer’s disease in a mouse model. This is according to a new study in the open access journal PLOS Biology by Rui Zhang of Air Force Medical University in Xian, Shaanxi, China. The results highlight […]

March 8, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 10 Feb 2023

Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio

This week, our guests are Romualda Stragienė, director at Innovation Agency Lithuania and Andrius Sliuzas, export key account manager of high tech industries at Innovation Agency Lithuania; 4basebio CEO Heikki Lanckriet; and Yoshitsugu Shitaka, chief scientific officer at Astellas. 4basebio 4basebio, a spinout of 2Invest AG in 2020, is a life sciences company engaged in […]

February 10, 2023

News and Trends 7 Feb 2023

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Feb 2023

Cancer Genomics: Technological innovation set to fuel research breakthroughs

By Neil Ward, vice President and general manager, PacBio EMEA We’ve known for a long time that genomic sequencing can strengthen our understanding of cancer’s highly complex and variable pathology. But to date, embedding genomics into cancer research has been challenging because of limitations in sequencing technology. But with recent innovations, this is changing. Genomic […]

February 1, 2023 - 3 minutesmins - By External Contributor

News and Trends 26 Jan 2023

Lupus treatment hope from Japanese miRNA research

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified two miRNAs that are downregulated in the disease and an uncommon situation that occurs in which multiple miRNAs regulate the same set of genes. Although […]

January 26, 2023 - 5 minutesmins - By Jim Cornall

Interview 23 Jan 2023

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […]

January 23, 2023 - 1 minutemin - By Jim Cornall

News and Trends 11 Jan 2023

AbbVie bets on Anima mRNA modulators to tackle cancer

AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators for three targets in oncology and immunology. Anima Biotech will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets, providing AbbVie exclusive rights to license and further develop and commercialize the programs. “This collaboration […]

January 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 6 Jan 2023

BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies

BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United Kingdom. The deal is set to benefit patients by speeding up clinical trials for personalized mRNA immunotherapies. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or […]

January 6, 2023 - 4 minutesmins - By Jim Cornall

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us